COVID-19 Vaccination Recommendations

 

Purpose

The purpose of this document is to provide guidance on COVID-19 vaccination for individuals with autoimmune rheumatic diseases in the Caribbean as vaccination programs are implemented. It is a living document that will be updated as more information becomes available. For most Caribbean countries the available vaccine is Oxford-AstraZeneca - a replication-deficient simian adenovirus vector, first approved for use by the Medicines and Healthcare products Regulatory Agency in the United Kingdom on December 30th 2020.

Methods

A task force consisting of 8 rheumatologists (see Appendix) was convened to review the literature and to address 4 questions-:

  1. Are COVID-19 vaccines safe to administer to individuals with rheumatic disease?
  2. Will these vaccines be effective in individuals with rheumatic disease?
  3. Are individuals with rheumatic disease/on immunosuppressive therapy at increased risk of COVID-19 infection?
  4. Are individuals with rheumatic disease/on immunosuppressive therapy at increased risk of worse outcomes with COVID-19?

Learn more (PDF)

Our Board of Directors 2018 - 2020

2018 - 2020


Previous Executive

President - Dr. Amanda King
Vice President - Dr. Cindy Flower
Treasurer - Dr. Lynda Tilluckdharry
Secretary - Dr. Sharon Dowell


Other directors were 

Dr. Nicole Johnson, Dr. / Prof. Eon Nigel Harris and Dr. Vincent Nwosa

Caribbean Association for Rheumatology
Bay Medical Centre
P.O. Box GM712
Castries | Saint Lucia

send us a message